20th Annual Industry/Academia
Precision Oncology Symposium
Date: March 21, 2024Location: La Jolla, California
Organized by Ida Deichaite, PhD
Dir. Translational Programs, Moores Cancer Center, Assistant Professor, Radiation Medicine & Applied Sciences, UC San Diego
Symposium Planning Committee
Ida Deichaite, PhD, UCSD
Fotis Asimakopoulos, MB BChir, PhD, UCSD
Napoleone Ferrara, MD, UCSD
Dan Kaufman, MD, PhD, UCSD
Jill Mesirov, PhD, UCSD
20TH ANNUAL SYMPOSIUM
Meet our 2024 Speakers!
Look at the 2024 Agenda in PDF!
Leaders in cancer research from around the world gathered for the 20th year of the Industry/Academia Precision Oncology Symposium, where they engaged with the latest high-impact science and multidisciplinary expertise in cancer treatment and research. The symposium’s longevity speaks to its value in the oncology and biotech community, with many attendees joining year after year. Past symposium leaders and frequent attendees reflected on the current industry trends.
20TH SYMPOSIUM PRESS RELEASE
Click for March 11 Press Release
San Diego, Calif.--(BUSINESS WIRE)--The Duane Roth Endowed Lecture Committee today announced that it will recognize Laura Shawver, Ph.D., as the 2024 Award Lecture recipient. The award will be presented by San Diego Mayor Todd Gloria during the 20th Annual Industry/Academia Precision Oncology Symposium on March 21 in La Jolla, California.
Dr. Laura Shawver is a healthcare pioneer who has created new paradigms in cancer research and treatment through her roles as a scientist, leader, patient and patient advocate. As an early career scientist, she conducted research on oncogenes, growth factors and signal transduction pathways. Following her own diagnosis and treatment for ovarian cancer in 2006, she founded The Clearity Foundation to help revolutionize ovarian cancer treatment and create a community of support for women living with the disease. Since her recovery from ovarian cancer, Dr. Shawver continues to seek ways to change the paradigm for cancer treatment through her leadership roles in biotech, both as a Chief Executive Officer and through serving on company Boards including those working on precision medicines, AAA ATPases, cytokines, cell therapy and mRNA therapies. She currently serves as President and Chief Executive Officer of Capstan Therapeutics, a biotechnology company dedicated to advancing in vivo reprogramming of cells through mRNA delivery using targeted lipid nanoparticles.
“We are thrilled to be recognizing Dr. Shawver as a pioneer in cancer drug development and as a champion for those within the patient community with limited treatment options and resources,” said Ida Deichaite, Ph.D., director of UC San Diego Moores Cancer Center’s Office of Industry Relations and organizer of the symposium. “Dr. Shawver’s unwavering commitment to the cancer patient community, including her work in both the biotech and nonprofit sector, is inspiring and embodies Duane Roth’s commitment to creating new treatment options in oncology.”
About the Duane Roth Endowed Award Lecture
The Duane Roth Endowed Award Lecture is bestowed upon patient-focused leaders in health care whose work has overcome numerous scientific, financial, institutional, political and cultural obstacles to create new paradigms in research and treatment. Named after Duane Roth, an esteemed leader in the biotech industry who was tragically killed following a bicycle accident in 2013, the award is given to those who demonstrate his deep commitment to innovation and the patient. Past recipients include: Napoleone Ferrara, M.D., UC San Diego; Kristen Hege, M.D., Bristol Myers Squibb; Dennis Carson, M.D., UC San Diego; Scott Gottlieb, M.D., FDA, American Enterprise Institute, New Enterprise Associates; Susan Band Horwitz, Ph.D., Albert Einstein College of Medicine; Carl June, M.D., University of Pennsylvania School of Medicine; Sandra Horning, M.D., Genentech; Dennis Slamon, M.D., Ph.D., UCLA Jonsson Comprehensive Cancer Center; Brian Druker, M.D., Knight Institute at Oregon Health and Science University; and Laura Esserman, M.D., UCSF Helen Diller Family Comprehensive Cancer Center. Biographies of past winners and their accomplishments are available online.
About the Industry/Academia Precision Oncology Symposium
Since 2005, UC San Diego Moores Cancer Center’s Office of Industry Relations annually organizes the Industry/Academia Precision Oncology Symposium— a unique forum where distinguished investigators, scientists, and clinicians join top industry decision-makers to discuss the latest breakthroughs in translational oncology research. Talks include personalized medicine, targeted therapy discoveries, collaborative clinical trials paradigms and case studies of previous successful collaborative projects. An interactive panel session comprised of industry and academia panelists and the concluding networking reception allow for further dialogue of ideas and the fostering of collaborative relationships.
About the UC San Diego Moores Cancer Center’s Office of Industry Relations
Industry Relations at UC San Diego Moores Cancer Center, a NCI-designated Comprehensive Cancer Center, builds relationships for collaborative translational oncology projects. With the power of industry/academia collaboration, the lead time and enormous costs of cancer therapy development are significantly reduced, overcoming numerous translational gaps that often cause clinical trials to fail. Industry Relations unifies the efforts of the sciences within cancer research to better stratify patients according to their biomarker profiles, reducing toxicity, improving drug development efficiency, minimizing extraneous costs and meeting patients' specific needs quickly.
Read at Businesswire.com
19TH SYMPOSIUM PRESS RELEASE
Click for April 20 Press Release
Napoleone Ferrara, MD, to be honored as the 2023 Duane Roth Achievement Award recipient
Levi Garraway, MD, PhD, to deliver keynote presentation, Waseem Qasim, MBBS, PhD, to present as honorable guest speaker
April 20, 2023 09:23 AM Eastern Daylight Time
LA JOLLA, Calif.--(BUSINESS WIRE)--Moores Cancer Center at UC San Diego Health and the Office of Industry Relations today announced that the 19th annual Industry/Academia Next Generation Precision Oncology Symposium will be held Thursday, April 27, at The Alexandria at Torrey Pines Conference Center. The Symposium serves as a forum for sharing scientific and medical advances in cancer research spanning multiple classes of therapies, with sessions focused on hematologic and solid tumors, immune oncology, cellular therapies and genomics.
As part of the event, Napoleone Ferrara, MD, Distinguished Professor, Senior Deputy Director for Basic Sciences, Moores Cancer Center, will be honored as the 2023 Duane Roth Achievement Award recipient. Dr. Ferrara is being recognized for leading advances in the development of bevacizumab (Avastin®) during his time at Genentech and will deliver a lecture titled, “Tumor Angiogenesis from Discovery to Therapy.”
In addition, the Symposium’s keynote speaker will be Levi Garraway, MD, PhD, Head of Product Development and Chief Medical Officer of Roche. Dr. Garraway, who previously was a co-founder of Foundation Medicine, will present about “Frontiers of Therapeutic Development.” The Symposium will also feature an honorable guest speaker, Waseem Qasim, MBBS, PhD, Professor of Cell & Gene Therapy for Institute of Child Health, UCL. Dr. Qasim will present about “Translational base editing for T cell immunotherapy.”
“We see the importance of this event as an opportunity for leading minds in cancer research to present new discoveries and find new ways to collaborate in the interest of helping patients, said Joseph A. Califano III, director of Moores Cancer Center.
“The symposium is a unique forum uniting life science innovators from around the world to brainstorm translational oncology research,” said Ida Deichaite, Ph.D., director of UC San Diego Moores Cancer Center’s Office of Industry Relations and an organizer of the symposium. “We are proud to hear from past attendees about a high number of collaborations and alliances stemming from the event that address the needs for accelerated research.”
The Symposium is a forum for leaders in cancer research to present their latest data and translation of research into clinical applications and lifesaving treatment approaches for patients. The Symposium’s emphasis on translational oncology and drug development unites discovery and clinical development researchers, facilitating alliances and partnerships to ultimately accelerate curative therapies that advance global cancer care. Organizers encourage sharing of unpublished data to accelerate research dissemination and discussions that support exchange of knowledge.
Talks presented at the symposium include:
About the Duane Roth Endowed Award Lecture
The Duane Roth Endowed Award Lecture is bestowed upon patient-focused leaders in health care whose work has overcome numerous scientific, financial, institutional, political and cultural obstacles to create new paradigms in research and treatment. Named after Duane Roth, an esteemed leader in the biotech industry, the award is given to those who demonstrate his deep commitment to innovation and the patient. Past recipients include Dennis Carson, MD, UC San Diego; Susan Band Horwitz, PhD, Albert Einstein College of Medicine; Scott Gottlieb, MD, 23rd Commissioner of the Food and Drug Administration; Carl June, MD, University of Pennsylvania School of Medicine; Sandra Horning, MD, head of global product development and chief medical officer, Genentech; Dennis Slamon, MD, PhD, UCLA Jonsson Comprehensive Cancer Center; Brian Druker, MD, Knight Institute at Oregon Health and Science University; and Laura Esserman, MD, UCSF Helen Diller Family Comprehensive Cancer Center. Biographies of past winners and their accomplishments are available online.
About the Next Generation Precision Oncology Symposium
Since 2005, UC San Diego Moores Cancer Center’s Office of Industry Relations annually organizes the Next-Generation Precision Oncology Symposium — a unique forum where distinguished investigators, scientists, clinicians and others in cancer research discuss the latest breakthroughs in translational oncology. Talks include personalized medicine, targeted therapy discoveries, collaborative clinical trials paradigms and case studies of previous successful collaborative projects. Interactive sessions and the concluding networking reception allow for further dialogue of ideas and the fostering of collaborative relationships. Learn more online.
About the UC San Diego Moores Cancer Center’s Office of Industry Relations
Industry Relations at UC San Diego Moores Cancer Center, a NCI-designated Comprehensive Cancer Center, builds relationships for collaborative translational oncology projects. With the power of industry/academia collaboration, the lead time and enormous costs of cancer therapy development are significantly reduced, overcoming numerous translational gaps that often cause clinical trials to fail. Industry Relations unifies the efforts of the sciences within cancer research to better stratify patients according to their biomarker profiles, reducing toxicity, improving drug development efficiency, minimizing extraneous costs and meeting patients' specific needs quickly.
Read at Businesswire.com
Symposium Summary
The Industry/Academia Precision Oncology Symposium is a unique forum uniting life science innovators from around the world to brainstorm translational oncology research. Presentations and discussions focus on how recent developments in oncology translate into clinical applications and lifesaving therapeutic options for cancer patients.
COI Policy: Disclosure of Relationships with Companies
The Symposium strives for independence, objectivity, transparency, and scientific rigor in all its activities through appropriate disclosure and management of financial relationships, among other things. The Symposium Policy for Relationships with Companies (COI Policy), in compliance with UC San Diego and University of California Office of the President (UCOP) COI policies (available at this link), was developed to help guide the management of potential conflicts, primarily through disclosure of all financial relationships that might result in actual, potential, or perceived conflicts of interest.
The Symposium requires participants in its activities—and all faculty and committee members— to disclose all of their financial relationships with for-profit health care companies. The Symposium’s Policy is not intended to create a presumption of impropriety based on the existence of financial relationships with companies, rather the goal is to achieve full transparency through the disclosure of those relationships. Although the Symposium Policy relies primarily on disclosure of financial relationships, it also recognizes that some relationships cannot be managed with disclosure alone and identifies additional management steps in this case.
The Symposium wants to help participants in its activities to successfully report their disclosures. To that end, the Symposium uses a general disclosure model, requiring disclosure of all relationships.